Market capitalization | $860.11b |
Enterprise Value | $885.71b |
P/E (TTM) P/E ratio | 113.04 |
EV/FCF (TTM) EV/FCF | 3,435.64 |
EV/Sales (TTM) EV/Sales | 22.76 |
P/S ratio (TTM) P/S ratio | 22.10 |
P/B ratio (TTM) P/B ratio | 63.44 |
Dividend yield | 0.50% |
Last dividend (FY23) | $4.52 |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
32 Analysts have issued a Eli Lilly and Company forecast:
32 Analysts have issued a Eli Lilly and Company forecast:
Jun '24 |
+/-
%
|
||
Net Profit | 2,967 2,967 |
68%
68%
|
|
Depreciation and Amortization | 414 414 |
13%
13%
|
|
Stock Compensation | 211 211 |
31%
31%
|
|
Operating Cash Flow | 1,466 1,466 |
132%
132%
|
|
Investments | 1,403 1,403 |
68%
68%
|
|
Dividend Paid | 1,172 1,172 |
15%
15%
|
|
Free Cash Flow | 241 241 |
327%
327%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Head office | United States |
CEO | David Ricks |
Employees | 43,000 |
Founded | 1876 |
Website | www.lilly.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.